Hepatocellular carcinoma is one of the deadliest cancers in the world and due to its growing incidence, additional focus is necessary in order to save lives. We know that majority of HCC cases occur in patients with previous cirrhotic liver. It’s therefore of utmost importance to prevent diseases that can progress to cirrhosis. Due to the complexity of HCC, selection of treatment depends on several factors, such as extent of the disease, location, underlying liver function and general condition of the patient. All important for establishing the development and prognosis of the disease. Curative therapies include surgical removal of the tumor lesion, liver transplantation and certain percutaneous ablative treatments. These therapies are aimed at patients who were diagnosed at an early stage of HCC. Patients with more advanced HCC are treated with minimally invasive therapies, systemic drugs or konservatively, which are aimed at improving quality of life and life expectancy. In the last 30 years, much of the medical development and innovation in minimally invasive procedures that are used throughout the world today, are methods pioneered by interventional radiologists. In this thesis we will explain various staging systems that are used to divide patients, cover treatment options that are available to patients with liver tumor, provide a detailed explanation of transarterial chemoembolization and other minimally invasive treatment modalities, and conclude with a discussion of the role of transarterial chemoembolization and other therapies in the battle of hepatocellular carcinoma & other liver tumors.